By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fiscal second-quarter revenues for Myriad Genetics rose 8 percent, driven by sales of its BRACAnalysis product, the company reported after the close of the market on Thursday.

For the three months ended Dec. 31, 2010, revenues for the molecular diagnostics firm rose to $100.4 million, compared to $92.8 million a year ago, surpassing consensus Wall Street estimates of $98.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.